Participated · Equity · Jun 2026

Beren Therapeutics P.B.C. is a founder-led biotech focused on discovery, development, and commercialization of cyclodextrin-based therapies that address defective intracellular cholesterol trafficking. Its lead program, adrabetadex, is under Priority Review by the U.S. FDA with a PDUFA target action date of November 17, 2026, and has been studied in clinical trials and expanded access programs since 2021. The company has built patient access and family support initiatives and intends to prepare for a potential U.S. commercial launch if adrabetadex is approved. Beren describes itself as a public benefit company that integrates patient, caregiver, clinician, and health-system needs into development and access planning. The recent $300 million financing package is intended to support commercial readiness and long-term care infrastructure and aims to position the company to be financially self-sustaining through potential commercialization. Beren is headquartered in Thousand Oaks, California.

Participated · Series B · May 2026

NUCLIDIUM focuses on copper isotopes for radiotheranostics, using copper-61 for imaging and copper-67 for therapeutic applications. Its lead programs are NU101 for metastatic castration-resistant prostate cancer and NU201 for metastatic breast cancer, both slated to begin therapeutic phase 1/2a trials this year. The company reports that diagnostic phase 1/2 trial data to date show strong momentum, according to CEO and co-founder Leila Jaafar. NUCLIDIUM operates sites in Basel and Munich and is currently in the clinical development phase. It plans to expand its international production and manufacturing network for diagnostics and therapy and to develop new target structures in preclinical work to address additional solid tumor types.

Participated · Series A · Feb 2026

Vienna-based Nyra Health has built myReha, an MDR Class IIa-certified software platform that lets patients train speech, cognition, fine motor skills, and everyday abilities with real-time, AI-generated feedback. The product is already deployed in more than 100 neurological clinics and is integrated into the German Pension Insurance’s standard care program, giving automatic reimbursement through 28 statutory and private insurers and theoretical access to over 40 million insured individuals. Proprietary speech models and continuous data collection let the system adapt therapy intensity and content to each patient’s performance, and a randomized controlled trial has shown significantly greater cognitive and language improvements versus standard care. Clinicians use Nyra Insights to monitor progress and adjust programs, while an AI Content Studio dynamically creates individualized therapy exercises. With ISO 13485 and ISO 27001 certifications and eleven peer-reviewed publications, the company positions itself as a clinically validated, data-driven leader in digital neurorehabilitation. Nyra Health plans to deepen integration with additional DACH clinic groups, expand reimbursement schemes across Germany, Austria, and Switzerland, and prepare a U.S. launch in partnership with an international pharmaceutical company. A separate €4.2 million research project with U.S. universities is advancing its multimodal AI models for therapeutic interaction and diagnostics.

Participated · Series B · Aug 2025

SNIPR BIOME is a clinical-stage biotech in Copenhagen that leverages a novel application of CRISPR-Cas technology to treat and prevent human disease via precision killing of bacteria or gene modification. Its SNIPR technology is applied in collaborations with CARB-X, the Gates Foundation, the Cystic Fibrosis Foundation, IPATH, SPRIN‑D and MD Anderson Cancer Center. The company focuses on microbial CRISPR-medicine, with programs aimed at infectious-disease targets. Led by CEO Christian Grøndahl, SNIPR Biome is advancing CRISPR-based therapeutic approaches toward the clinic. The company recently completed a significant Series B raise, strengthening its balance sheet to continue development. It intends to use the new funds to support a CRISPR-Cas therapy specifically targeting airway infections caused by Pseudomonas aeruginosa in people with cystic fibrosis. SNIPR Biome is a Copenhagen-based clinical-stage biotech pioneering CRISPR-Cas–armed phages (CAPs) as precision medicines to prevent and treat bacterial infections and to modify microbiomes. The company has developed an existing CRISPR-armed phage cocktail, SNIPR001, comprising four CAPs that broadly target Escherichia coli and will leverage this in the new project. SNIPR draws from an extensive phage library with broad antibacterial activity against E. coli and Klebsiella pneumoniae strains sourced from sites in low- and middle-income countries (LMICs). SNIPR was the first company to orally dose humans with a CRISPR therapeutic and holds US and European patents for the use of CRISPR targeting microbiomes. The company works with collaborators including Novo Nordisk, CARB-X, SPRIN-D, and MD Anderson Cancer Center. With new Gates Foundation funding, SNIPR plans to develop microbiome-directed CAPs aimed at reducing gut entero-pathogen burden to improve environmental enteric dysfunction (EED) and pregnancy outcomes in LMICs. SNIPR Biome pioneers precision medicines using CRISPR/Cas for microbial gene therapy, focusing on designer phage and bacteria to edit or kill target microbes. Its lead product, SNIPR001, is a CRISPR-armed phage therapeutic that selectively targets E. coli in the gut and aims to prevent E. coli bloodstream infections in hematological cancer patients. Preclinical data published in Nature Biotechnology showed selective removal of antibiotic-resistant E. coli without off-target effects, and an interim Phase 1 in healthy subjects demonstrated safety, target engagement, and dose-dependent fecal recovery. SNIPR001 has received Fast-Track designation from the FDA for prophylaxis of bloodstream E. coli infections in patients with hematological malignancy at risk of neutropenia. The company collaborates with partners including Novo Nordisk, CARB-X, SPRIN-D, and MD Anderson, and states it was the first to orally dose humans with a CRISPR therapeutic and to obtain US and European patents for CRISPR targeting of microbiomes. The recent funding will support advancing SNIPR001 into patient trials and underpin a further significant fundraise to continue development of its AMR and gut-directed pipeline. SNIPR BIOME ApS is a CRISPR- and microbiome-biotechnology company based in Copenhagen, Denmark. Its lead candidate, SNIPR001, is being developed to prevent Escherichia coli infections in cancer patients, particularly those with hematological malignancies. The program aims to eradicate E. coli that can cause life-threatening bloodstream infections in patients weakened by disease and chemotherapy. SNIPR BIOME is advancing SNIPR001 through preclinical development under an award from CARB-X. The company may receive milestone-based additional funding tied to project progress. The work focuses on an engineered drug approach that leverages the company’s CRISPR and microbiome expertise. Snipr Biome is developing CRISPR-based therapeutics that use bacteria's CRISPR/Cas systems to selectively target and kill bacteria with defined DNA sequences. The company has secured a series of patents on altering microbiota for purposes including immune modulation. Snipr plans to advance its CRISPR microbiome drugs into clinical trials and has been refining its R&D strategy following technology validation. It will initially focus on precision medicines for difficult-to-treat infections and precision microbiome modulation in autoimmunity and cancer. The technology also has potential applications against multi-drug-resistant bacteria and in food-industry quality control. Snipr recently raised $50 million to support these development efforts.

Led · Equity · Apr 2025

HepaRegeniX GmbH is a Tuebingen, Germany–based clinical-stage biopharma developing orally available small-molecule therapies that stimulate rapid liver regeneration. Its lead candidate, HRX-215, selectively inhibits MKK4 and is being developed to prevent post-hepatectomy liver failure, enable transplantation with smaller living donor grafts, and treat severe alcohol-associated hepatitis. HRX-215 is currently in a combined Phase Ib/IIa trial, and the company plans to use new funding to complete Phase Ib and advance the Phase IIa study. Beyond HRX-215, HepaRegeniX is developing HRX-233 to overcome kinase inhibitor resistance in KRAS-driven tumors. The company is led by CEO Elias Papatheodorou and has demonstrated safety of HRX-215 in clinical trials to date. HepaRegeniX raised €21.5M to support these clinical development milestones. HepaRegeniX is developing novel regenerative therapies targeting acute and chronic liver diseases based on inhibition of Mitogen-Activated Protein Kinase Kinase 4 (MKK4). The company has discovered multiple drug candidates centered on this proprietary molecular target. Its lead candidate, the MKK4 inhibitor HRX-215, recently completed Phase 1 clinical testing. HepaRegeniX intends to use the new funding to advance the clinical development of HRX-215. The company operates from Tuebingen, Germany and focuses on unlocking hepatocyte regenerative capacity even in severely diseased livers by suppressing MKK4. Recent financing strengthens its runway for upcoming clinical work. HepaRegeniX is a preclinical-stage company focused on developing a novel therapy for acute and chronic liver diseases. The company’s lead approach targets Mitogen-Activated Protein Kinase 4 (MKK4), a key regulator of liver regeneration. Suppression of MKK4 is reported to unlock the regenerative capacity of hepatocytes even in severely diseased livers. The therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tübingen. Led by CEO Dr. Michael Lutz, HepaRegeniX has discovered and developed several preclinical drug candidates based on this proprietary molecular target. The company closed an over €11M Series B and intends to use the funds to advance its MKK4 inhibitor into clinical testing later in 2020. HepaRegeniX GmbH is developing a therapeutic approach targeting liver regeneration by inhibiting MKK4. The company has acquired worldwide exclusive rights to the related IP discovered by Prof. Lars Zender and his research group at the University Hospital Tübingen. In collaboration with the Zender group and the medicinal chemistry group of Eberhard‑Karls University of Tübingen, HepaRegeniX has identified its first small‑molecule MKK4 inhibitors. The company plans to use the Series A proceeds to advance medicinal chemistry discovery programs and preclinical development of drug candidates through IND filing. Management, led by CEO Dr. Wolfgang Albrecht, is targeting a first clinical study for the treatment of acute liver failure in 2019. The company completed a €9m Series A financing to fund these efforts.